XML 29 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring
 12 Months Ended
Sep. 30, 2020
Restructuring and Related Activities [Abstract]  
Restructuring
(3)
Restructuring
During the second quarter of fiscal 2018, the Company began implementation of a plan to realign its business structure into two business units, Diagnostics and Life Science, supported by a global corporate team. Since that time and as part of this plan, certain functions and locations within both business units have been streamlined, including: (i) the elimination of certain executive management and commercial sales positions; (ii) the closing of Life Science locations in Taunton, Massachusetts and Singapore, the operations of which were transferred to our existing locations in Memphis, Tennessee and London, England, respectively; and (iii) the transfer of certain functions performed in the Billerica, Massachusetts Diagnostics facility to the corporate headquarters in Cincinnati, Ohio. Further restructuring costs were incurred in fiscal 2019 and fiscal 2020, as refinements to each business unit’s cost structure continued to be made and the Company incurred severance payment obligations relating to the transition of its previous chief financial officer.
As a result of these activities, restructuring costs totaling $
687
, $2,839 and $6,332 were recorded during fiscal 2020, 2019 and fiscal 2018, respectively, the details of which are as follows:
 
Year Ended September 30,
   
2020
      2019      2018  
Severance, other termination benefits and related costs
   
$
601
      $ 2,046    $ 5,012
Lease and other contract termination fees
   
 
86
        54      353
Loss on fixed asset disposals and inventory scrap
   
 
—
       528      225
Other
   
 
—
        211      742
  
 
 
     
 
 
     
 
 
  
Total
   
$
687
      $ 2,839    $ 6,332
  
 
 
     
 
 
     
 
 
  
The above table does not include $2,374 of CEO transition costs incurred in fiscal 2018, which primarily represents the compensation and benefits for our previous Executive Chairman and CEO, Mr. John A. Kraeutler, throughout fiscal 2018, the period during which we also
had
 the compensation and benefits
of
our current CEO, Mr. Jack Kenny, who began employment at the beginning of fiscal 2018. These CEO transition costs and the restructuring costs set forth in the table above comprise the $8,706 of restructuring costs set forth in the accompanying Consolidated Statement of Operations for fiscal 2018.
A reconciliation of the changes in the liabilities associated with the restructuring charges from September 30, 2018 through September 30, 2020 is as follows:
 
    
Employee
Separation
and
Related
Costs
     
Lease and
Other
Contract
Termination
Fees
     
Other
     
Total
  
Balance at September 30, 2018
    $ 987      $ 33      $ 6      $ 1,026  
Restructuring charges
      2,810        54         
211
        3,075  
Reversal of prior period accruals
      (401 )         
(32
)
 		        
(61
)
 		      (494 ) 
Payments
      (2,386 )       (43 )       (42 )       (2,471 ) 
  
 
 
     
 
 
     
 
 
     
 
 
  
Balance at September 30, 2019
    $ 1,010      $ 12        114      $ 1,136  
Restructuring charges
      642        86        —          728  
Reversal of prior period accruals
      (41 )       —          —          (41 ) 
Payments
      (1,565 )       (98 )       (114 )       (1,777 ) 
  
 
 
     
 
 
     
 
 
     
 
 
  
Balance at September 30, 2020
    $ 46      $ —        $ —        $ 46